Seattle Lumen Bioscience landed $16.2 million from the U.S. Department of Defence. The funding will go toward trials of Lumen’s drug aimed at C. difficile infection. Lumen, who announced the funding on October 17th, is enrolling about 375 patients for this study and plans to start recruiting patients in the fourth quarter. Lumen Bioscience co-founder and CEO Brian Finrow said the company is looking for people newly diagnosed with the infection for its trials.
